JANSSEN RESEARCH & DEVELOPMENT, LLC

A 69-year-old man from Stockport shows no cancer signs 6 years after joining the FLAIR trial at The Christie NHS Foundation Trust. The trial tested if targeted drugs (venetoclax and ibrutinib) were more effective than chemotherapy for untreated chronic lymphocytic leukaemia (CLL). Results showed improved survival and remission rates, with fewer side effects compared to chemotherapy. The trial, led by the University of Leeds, involved 1500 participants across 100 UK hospitals and was funded by Cancer Research UK, Janssen, and AbbVie.

DelveInsight's report on Urothelial Carcinoma Market (2020-2034) highlights market trends, epidemiology, and key companies/therapies. The market size was ~USD 900 million in 2023, expected to grow significantly. Key companies include Merck, Bristol Myers Squibb, and others. Therapies like KEYTRUDA and OPDIVO are prominent. The U.S. leads in market share and incident cases. Pipeline candidates and increased awareness drive market growth.

Johnson & Johnson submitted two sBLAs for guselkumab, seeking FDA approval for pediatric indications: moderate to severe plaque psoriasis in children aged 6 and older, and active juvenile psoriatic arthritis in children aged 5 and older. Guselkumab selectively binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor, and has previously been approved for adult PsO and PsA.

Guselkumab (Tremfya) demonstrated effectiveness in clearing overlooked plaque psoriasis in SPECTREM trial, achieving optimal IGA scores in 74.2% of patients vs. 12.4% with placebo. In GRAVITI study, guselkumab showed rapid onset of action in Crohn disease, with 56.1% achieving clinical remission vs. 21.4% with placebo. Guselkumab is the first fully human, dual-acting monoclonal antibody approved for ulcerative colitis.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

DARZALEX FASPRO® in maintenance therapy significantly increased MRD-negativity rate at 12 months compared to lenalidomide alone, improving 30-month progression-free survival in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.

Updated MARIPOSA-2 study results show amivantamab plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.